Anti-programmed death 1 antibody in the treatment of coexistent Mycobacterium fortuitum and lung cancer: A case report

Figure 1 Expression of programmed death ligand 1 (immunohistochemical staining, Dako 22C3). A: Positive controls × 200; B: Negative controls × 200; C: Tumor samples hematoxylin and eosin × 100; D: Tumor samples immunohistochemistry × 200.

Figure 2 Imaging findings during treatment. July 2, 2019: prior to treatment; September 26, 2019: two cycles after treatment; July 1, 2020: 14 cycles after treatment; →: New irregular subpleural mass.

Figure 3 Pathology diagnosis of the second biopsy (× 400). A: Carbon dust deposition; B: Invasion of lymph cells; C: Fibrosis.